Tj Darentang USD announcement, as one of the shareholders of Tianjin Pharmaceuticals Group Finance Co., Ltd., intends to increase capital by 0.15 billion yuan in proportion to its existing shareholding. After the capital increase, the company's shareholding ratio will remain at 30%. This transaction constitutes a related party transaction, but does not constitute a significant asset restructuring and does not require approval by the shareholders' meeting.